Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
George DJ, Saad F, Pieczonka C, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Shore ND February 18, 2022 ASCO GU 2022 Prostate Cancer

Efficacy and Safety of Relugolix in Black Men with Advanced Prostate Cancer: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide 

View Presentation View Abstract Plain Language Summary
Poster
Shore ND, George DJ, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Lee J, Hanson S, Saad F February 18, 2022 ASCO GU 2022 Prostate Cancer

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Subgroup Analysis from the Phase 3 HERO Study

View Presentation View Abstract Plain Language Summary
Poster
Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A February 18, 2022 ASCO GU 2022 Prostate Cancer

Overall survival in patients with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus androgen deprivation therapy by high or low disease volume and progression to metastatic hormone-sensitive prostate cancer (M0 at diagnosis) or de novo metastatic hormone-sensitive prostate cancer (M1 at diagnosis): post hoc analysis of the phase 3 ARCHES trial

View Presentation View Abstract Plain Language Summary
Poster
Morgans AK, Hong A, Murty S, El-Chaar N, Ramaswamy K, Coutinho AD, Nimke D, Freedland SJ February 18, 2022 ASCO GU 2022 Prostate Cancer

Prostate-Specific Antigen Outcomes in Black and White Chemotherapy-Naïve Prostate Cancer Patients Treated with Enzalutamide

View Presentation View Abstract Plain Language Summary
Poster
De La Cerda J, Migoya E, Brown B, Lu S, Zohren F, Tutrone R, Dunshee C February 18, 2022 ASCO GU 2022 Prostate Cancer

Relugolix in Combination with Abiraterone Acetate, Apalutamide, or Docetaxel in Men with Advanced Prostate Cancer (aPC): A Phase 1, Three-Part, Open-Label, Parallel-Cohort Study 

View Presentation View Abstract Plain Language Summary
Poster
Dorff T, Fizazi K, Laird AD, Barthelemy P, Delva R, Maruzzo M, Stirling A, Machiels J-P, Dumez H, Renard V, Hopkins J, Albacker LA, Chen H-C, Healy C, Chelliserry J, van Oort IM, Scagliotti G, de Bono JS, Mehra N February 18, 2022 ASCO GU 2022 Prostate Cancer

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—exploration of germline DDR alteration landscape and potential associations with antitumor activity 

View Presentation View Abstract Plain Language Summary
Poster
Agarwal N, Azad AA, Fizazi K, Mateo J,  Matsubara N, Shore ND, Chakrabarti J,  Chen H-C, Lanzalone S, Niyazov A, Saad F, for the TALAPRO-3 investigational group  February 18, 2022 ASCO GU 2022 Prostate Cancer

TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide (ENZA) Plus Talazoparib vs Placebo Plus ENZA in Patients with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

View Presentation View Abstract Plain Language Summary
Poster
Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Brown B, Lu S, Shore ND February 18, 2022 ASCO GU 2022 Prostate Cancer

Testosterone Recovery for Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

View Presentation View Abstract Plain Language Summary
Poster
Barata P, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, Niyazov A, Ivanova J February 18, 2022 ASCO GU 2022 Prostate Cancer

Treatment Patterns Among Men with Metastatic Castration- Resistant Prostate Cancer (mCRPC) in the United States (US)

View Presentation
Poster
Barata P, Leith A,  Ribbands A, Montgomery R, Last M, Arondekar B, Niyazov A,  Ivanova J February 18, 2022 ASCO GU 2022 Prostate Cancer

Treatment Trends Among Men with Metastatic Castration- Sensitive Prostate Cancer (mCSPC): Results from the US Component of an International Study

View Presentation